Search results
Showing 1201 to 1215 of 1961 results for nice guidelines
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
asthma guideline – one year on Podcasts 29 January 2026 Listen About this episode Developed collaboratively by the British Thoracic...
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Mersey Burns for calculating fluid resuscitation volume when managing burns (MIB58)
NICE has developed a medtech innovation briefing (MIB) on Mersey Burns for calculating fluid resuscitation volume when managing burns
consider the possibility of hearing loss.The evidence review for the NICE guideline on adult hearing loss highlighted...
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Help us improve NICE: take part in research to help us develop better products and services.
Help us improve NICE: take part in research to help us develop better products and services.
NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)
NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .